August 26, 2019
Aug 27 (Reuters) - AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with long-term kidney disease.
Farxiga, already one of AstraZeneca's top 10 drugs by sales, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine. (Reporting by Justin George Varghese in Bengaluru; Editing by Bernard Orr)(c) Copyright Thomson Reuters 2019. Click For Restrictions - https://agency.reuters.com/en/copyright.html